Krystal Biotech (KRYS) Change in Acquisitions & Divestments (2019 - 2026)

Krystal Biotech (KRYS) has 8 years of Change in Acquisitions & Divestments data on file, last reported at $103.6 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments rose 16.66% year-over-year to $103.6 million; the trailing twelve-month figure through Mar 2026 stood at $390.4 million (up 20.6% YoY), and the FY2025 full-year result was $375.6 million, up 25.83% from the prior year.
• Change in Acquisitions & Divestments grew to $103.6 million in Q1 2026, from $85.8 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $161.2 million in Q2 2023 to a low of $24.0 million in Q1 2022.
• A 5-year average of $90.5 million and a median of $88.8 million in 2025 frame the typical range for Change in Acquisitions & Divestments.
• Across the five-year window, Change in Acquisitions & Divestments jumped 4992.62% in 2022 and sank 58.83% in 2024, its largest moves.
• Tracing KRYS's Change in Acquisitions & Divestments over 5 years: stood at $104.1 million in 2022, then fell by 28.33% to $74.6 million in 2023, then decreased by 18.9% to $60.5 million in 2024, then jumped by 41.77% to $85.8 million in 2025, then rose by 20.79% to $103.6 million in 2026.
• Business Quant data shows KRYS's Change in Acquisitions & Divestments at $103.6 million in Q1 2026, $85.8 million in Q4 2025, and $95.8 million in Q3 2025.